Hot Natural Products & Bioactive Compounds
BioCrick offers high-purity natural products and bioactive compounds for scientific research. Our natural product collection includes compounds derived from plants, microorganisms and other biological sources and is widely used in pharmacological, biochemical and drug discovery research.
Natural products remain an important source of bioactive molecules and drug leads. BioCrick provides researchers with high-quality natural product compounds together with catalog numbers, product information and biological activity data.
Hot Products from BioCrick
Showing 401 - 408 of 9359 hot products
| Catalog No. | Product Name |
|---|---|
| BCC2330 | Torcetrapib |
|
Inhibitor of cholesteryl ester transfer protein (CETP). Also impairs endothelial function in vivo; induces hypertension and inhibits acetylcholine-induced vasodilation in rabbit central ear artery.
|
|
| BCC2333 | A922500 |
|
Diacylglycerol acyltransferase 1 (DGAT-1) inhibitor (IC50 values are 7 and 24 nM at human and mouse DGAT-1 respectively) that is devoid of activity at DGAT-2, ACAT1 or ACAT2. Induces significant weight loss without altering food intake, and decreases liver and plasma triglyceride levels in vivo. Orally active.
|
|
| BCC2334 | Tolcapone |
|
COMT inhibitor. Inhibits both brain and peripheral COMT. Also binds transthyretin (TTR) with high affinity (Kd1 and Kd2 values are 21 and 58 nM, respectively). Inhibits TTR aggregation in human plasma and prevents TTR-induced cytotoxicity in vitro. Stabilizes TTR in mice and humans in vivo. Orally bioavailable.
|
|
| BCC2338 | VER 155008 |
|
Novel adenosine-derived inhibitor of Heat Shock Protein 70 (Hsp70) (IC<sub>50</sub> = 0.5 <span class='symbol'>μ</span>M). Inhibits cell proliferation of multiple human tumor cell lines <em>in vitro</em>. Also binds Hsc70 and Grp78; displays selectivity against Hsp90<span class='symbol'>β</span> (IC<sub>50</sub> >200 <span class='symbol'>μ</span>M for Hsp90<span class='symbol'>β</span>).
|
|
| BCC2340 | BMS 299897 |
|
Orally active, potent <span class='symbol'>γ</span>-secretase inhibitor (IC<sub>50</sub> = 12 nM). Inhibits A<span class='symbol'>β</span>40 and A<span class='symbol'>β</span>42 formation <em>in vitro</em> (IC<sub>50</sub> values are 7.4 and 7.9 nM respectively) and reduces A<span class='symbol'>β</span> in the brain, plasma and cerebrospinal fluid <em>in vivo</em>. Exhibits no Notch toxicity. Brain penetrant.
|
|
| BCC2341 | Compound W |
|
Inhibitor of <span class='symbol'>γ</span>-secretase; causes a decrease in the released levels of A<span class='symbol'>β</span>42 and notch-1 A<span class='symbol'>β</span>-like peptide 25 (N<span class='symbol'>β</span>25).
|
|
| BCC2342 | Flurizan |
|
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits <span class='symbol'>γ</span>-secretase activity. Selectively lowers A<span class='symbol'>β</span>42 levels in human neuroglioma cells; displays no effect on A<span class='symbol'>β</span>40 levels at a concentration of 100 <span class='symbol'>μ</span>M.
|
|
| BCC2343 | JLK 6 |
|
Inhibitor of <span class='symbol'>γ</span>-secretase that selectively inhibits <span class='symbol'>β</span>APP cleavage without affecting other <span class='symbol'>γ</span>-secretase-mediated pathways. Prevents recovery of A<span class='symbol'>β</span>40 and A<span class='symbol'>β</span>42 from HEK293 cell overexpressing wild-type or Swedish-mutated <span class='symbol'>β</span>APP (IC<sub>50</sub> ~ 30 <span class='symbol'>μ</span>M) but displays no effect on Notch cleavage and Notch-mediated intracellular signaling. Displays no activity on BACE1, BACE2, <span class='symbol'>α</span>-secretase, the proteosome or GSK3<span class='symbol'>β</span>.
|
|